The Acting President of the Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF) discusses genetic biomarkers and precision medicine. These biomarkers offer vital information about diseases, particularly cancer, which allows for more personalized treatments. The interview with the Acting President, Cristina Rodríguez-Antona, explains how biomarkers can improve medical treatments in the National Health Service by increasing the effectiveness and safety of preventive, diagnostic, and therapeutic strategies.
Rodríguez-Antona emphasizes that genetic biomarkers play a critical role in identifying individuals with a predisposition to certain diseases, allowing for more effective preventive interventions. Moreover, the use of these markers has the potential to optimize health system resources by directing specific treatments to those who would benefit most.
By implementing genetic biomarkers in the National Health Service, the interview highlights how adverse side effects of treatments can be reduced, thus enhancing the quality of life for patients. This aims to improve healthcare systems and reduce healthcare costs in the long term.
Ethical challenges associated with incorporating genetic information into the health system are also addressed, with emphasis on ensuring a secure framework for the use of genetic and medical tests. Additionally, the economic impacts of using genetic biomarkers in the National Health Service are discussed, emphasizing the initial costs and the long-term savings in ineffective or incorrect treatments.
Overall, the interview with Cristina Rodríguez-Antona provides valuable insights into the importance of genetic biomarkers in precision medicine and personalized medical care, and considers the broader implications on healthcare systems and patients.